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Telangiectasiaa b s t r a c t
Purpose: The aim of this study was to evaluate whether treatment with a local potent corticosteroid dur-
ing adjuvant external radiotherapy (ERT) of breast cancer is associated with late skin toxicity.
Material and methods: Sixty patients (32 treated with potent corticoid cream versus 28 controls treated
with moisturizer) who had been included in a randomized study on prophylactic local corticosteroid
treatment under adjuvant ERT in 2009 and 2010 were subjected to a follow-up study in 2016.
Assessments of skin texture were registered according to the Late Radiation Morbidity Scoring
Scheme (RTOG). Dryness, skin colour and skin thickness were objectively measured using non-invasive
instruments. The patients were assessed for differences between their treated and untreated
breasts.
Results: Skin atrophy was not noticed in any of the 60 patients. Objective instrumental measurements did
not reveal any significant differences in skin dryness, colour, pigmentation or skin thickness over the
average follow-up time of six years. Clinical assessment based on the RTOG scoring system revealed that
the odds ratio of having late skin problems in patients treated with moisturizer compared to patients
treated with corticosteroid was 3.2 (95% CI: 1.0–10.1).
Patients reported minor cosmetic dermatological sequelae. Seven patients developed telangiectasia,
which caused cosmetic inconvenience.
Conclusion: In this study, prophylactic corticosteroid treatment to ameliorate radiation dermatitis during
adjuvant ERT of breast cancer was not associated with an increase in late skin toxicity nor did it result in
skin atrophy. This study is limited by its small sample size, and the risk for false positive findings.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Adjuvant external radiotherapy (ERT) is an essential component
of breast cancer treatment. However, ERT often causes acute, con-
sequential late or chronic skin reactions [1–3]. Acute toxicity man-
ifesting as redness, dryness, desquamation and moist
desquamation within the treated skin area develops within the
first weeks of ERT [4]. The onset of chronic skin reactions has a long
latency from months to several years after ERT [1]. Skin atrophy,
fibrosis, changes in pigmentation, telangiectasia and skin cancercan develop [5]. The incidence of long-term adverse effects on
the skin varies from 5 to 30% for fibroses and telangiectasia [6].
There is no clear cut association between the degree of radio
dermatitis and the development of late reactions [7]. However,
moist desquamation has been shown to be correlated with the
development of telangiectasia but did not influence the extent of
fibrosis [8]. Many studies have shown that prophylactic treatment
with a potent corticosteroid cream ameliorates acute radio der-
matitis [9–12]. However, long-term local safety, especially the
development of skin atrophy, is an issue of concern [13]. To our
knowledge, no studies have assessed the long-term skin effects
of corticosteroid treatment administered in parallel with ERT.
The aim of this study was to evaluate whether treatment with a
local potent corticosteroid during adjuvant ERT of breast cancer is
associated with late skin toxicity.
10 E. Ulff et al. / Clinical and Translational Radiation Oncology 7 (2017) 9–12Material and methods
The study was performed from September 2016 to December
2016. Patients treated with ERT for breast cancer in 2009 and
2010 were invited to participate. They had been included in a ran-
domized study on prophylactic local treatment using either a
potent corticosteroid (betamethasone 0.1%) or a moisturizer
(brand name Essex) [14]. Patients underwent adjuvant ERT with
50 Gy/25 fractions after initial mastectomy or breast-preserving
surgery. In some patients, the radiation field was extended to the
armpit and the supraclavicular fossa. Patients who had undergone
mastectomy received a 3 cmmarginal bolus around the scar. When
the bolus was used, patients received 105–110% of the scheduled
dose corresponding to the volume beneath the bolus of 55 Gy/25
fractions. Patients younger than 40 years of age and patients who
underwent a surgery that was not radically performed were given
a boost of 16 Gy/8 fractions, according to national guidelines [15].
Acute radiodermatitis was assessed by using the Radiation Morbid-
ity Scoring Scheme from the Radiation Toxicity Oncology Group
(acute RTOG) at the end of ERT. This scoring system ranks dermati-
tis signs fromminor signs (grade 1) to severe signs (grade 4). Acute
RTOG was stratified into two groups: 0–1 (mild) and 2–3 (severe).
Out of 102 patients participating in the original study, 42 were
not included in the present study due to the following reasons: 14
had died (10 due to metastatic disease of internal organs, one due
to loco-regional recurrence and pulmonary metastases, and three
due to other diseases), seven did not respond after contacting, five
lived in other counties, 10 could not participate for practical rea-
sons, and six refused to participate. Thus, 60 patients were
included in the present study. All patients obtained a study infor-
mation letter and thereafter were asked by phone to participate
in the study. Written informed consent was signed on the patients’
first visit. All patient data were recorded in case report forms. Base-
line data were collected on the first visit to the clinic and saved in
Excel files. Demographic data and treatment provided to the 60
patients are shown in Table 1.Assessments
Skin texture was registered according to the Late Radiation
Morbidity Scoring Scheme from the Radiation Toxicity Oncology
Group (Late RTOG), which has two separate evaluation scales,
one for registration of changes of the dermis and epidermis, and
the other for registration of changes of subdermal structures. Der-Table 1
Distribution of surgical procedures, ERT, chemotherapy and endocrine treatment in
the two treatment groups for the 60 patients.
Treatment groups Corticosteroid Moisturizer Total number
of patients
Study population 28 32 60
Median age, years (range) 67 (42–75) 65 (33–80)
Surgical procedures
Mastectomy, modified 9 10 19
Breast preserving surgery 19 22 41
ERT
Chest wall with bolus 9 10 19





Without chemotherapy 15 22 37
FEC every third week x 3, and
paclitaxel weekly x 12
13 10 23
Endocrine therapy after ERT
Tamoxifen or/and aromatase
inhibitors
23 21 44mal and epidermal changes were registered as follows: grade 0:
none; grade 1: slight atrophy, pigmentation change, some hair
loss; grade 2: patch atrophy, moderate telangiectasia, total hair
loss; grade 3: marked atrophy, gross telangiectasia; and grade 4:
ulceration.
Subdermal structures were registered as follows: grade 0: none;
grade 1: slight induration and loss of subcutaneous fat; grade 2:
moderate fibrosis but asymptomatic, slight field contracture,
<10% linear reduction; grade 3: severe induration and loss of sub-
cutaneous fat, slight field contracture, >10% linear reduction; and
grade 4: necrosis [16].
The late RTOG values noticed for skin and subcutaneous tissue
were merged into two groups, RTOG = 0 and RTOG > 0, and
patients treated with corticosteroid versus moisturizer were
compared.
A dermatologist who had no information regarding the result of
the acute RTOG during ERT assessed late RTOG. Clinical examina-
tions included registration of any tumour in the skin of the treated
area.
The differences in cosmetic features (skin texture and colour)
between the treated and untreated breasts of patients were
assessed by the patients as follows: grade 1: almost identical;
grade 2: minimal difference; grade 3: fair; and grade 4: substantial
difference.
The group of patients who underwent mastectomy were not
asked about cosmetic outcomes.
Skin thickness was measured using 20 MHz Ultrasound (Der-
mascan C, Cortex Technology, Hadsund, Denmark) [17,18]. Scans
were obtained in four different sites in the ERT-treated field, and
three measurements were made for each scan. Thus, skin thickness
was considered the mean of 12 recordings. Scans were taken at
least 2 cm from the surgical scar [19]. Dryness of the epidermis
was measured as electrical capacitance using a Corneometer CM
820, (Courage-Khazaka, Cologne, Germany) [20]. Five measure-
ments were recorded at prefixed locations and averaged.
Redness (a⁄) and skin pigmentation (L) were measured with a
narrow band Colormeter (DSM II ColorMeter, Cortex Technology,
Hadsund, Denmark) [21]. Four recordings were made at prefixed
locations and averaged.
All recordings by non-invasive instrumental methods were
made in the ERT-treated field and symmetrically on the healthy
breast. In the final evaluation, measurements obtained on the
ERT-treated side were considered with historical information, i.e.,
treatment with corticosteroids or moisturizer.
Adjuvant chemotherapy and/or anti-hormonal treatments after
ERT were recorded.Statistics
Descriptive statistics were used to describe the patient popula-
tion. Paired t-tests were used to evaluate differences in skin char-
acteristics between treated and untreated breast, for which each
treated patient also served as her own control. For differences in
treatment with steroid or moisturizer, t-tests were performed on
the group level. A p-value 0.05 was considered statistically
significant.Ethic
The study protocol, patient information and consent forms were
reviewed and approved by the Regional Ethics Committee no.
2014/449-32 at the Linköping University and by the Swedish Med-
ical Products Agency (EudraCT 2009-018059-18) prior to the inclu-
sion of patients. The study was conducted in accordance with the
protocol, regulatory requirements, and ethical principles of the
Table 2
Dryness, redness, pigmentation and skin thickness characteristics and differences in dryness, redness, pigmentation and skin thickness after ERT in combination with treatment














Dryness, (Capacitance) 69.6 65.2–74.0 70.1 66.9–73.2 0.44 4.8 to 5.7 0.86 69.9 67.5–72.3
Redness colorimeter (a*) 10.6 9.4–11.8 9.9 9.0–10.8 0.19 1.6 to 1.6 0.98 10.2 9.1–11.4
Pigmentation colorimeter (L) 29.5 28.4–30.6 29.8 28.4–31.0 0.3 1.3 to 1.9 0.71 29.0 28.2–29.9
Skin thickness (mm) ultrasound 1.28 1.17–1.39 1.20 1.12–1.29 80.1 214.2 to 54.1 0.23 1.17 1.08–1.27
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Results
The average observation period of patients treated in 2009–
2010 with ERT, corticosteroids or moisturizer and included in the
present study was six years (mean of 76 months, median of 77
months, range 71–83). No skin cancers or loco-regional recurrence
of breast cancer were observed.
Instrumental measurements and assessment by RTOG
No major differences were found between the ERT-treated and
untreated breasts (paired t-test, not reported here) in skin capaci-
tance indicating dryness, colorimetric recordings indicating red-
ness, or pigmentation and skin thickness measured by ultrasound
(Table 2).
Late RTOG, skin
Clinical signs of skin atrophy were not observed in any of the 60
patients. Ten out of sixty patients (17%) had other noticeable skin
changes. Three patients (5%) had altered pigmentation (grade 1)
and seven (12%) patients had telangiectasia (grade 3). All seven
patients with telangiectasia had undergone mastectomy and ERT
to the chest wall and to the axilla and fossa. Telangiectasia was dis-
tributed in the bolus area, in the fossa and in the suprascapular
area [15]. All seven patients had acute RTOG 2–3.
Late RTOG, subcutaneous tissue
Slight fibrosis of grade 1 was observed in 13 (21%) patients.
Six out of 28 patients treated with a corticosteroid had late
RTOG grade > 0 compared to 15 out of 32 treated with moisturizer,
odds ratio of 3.2 (95% CI: 1.0–10.1). Nine-teen out of 43 patients
with acute RTOG 2–3 (severe) had late RTOG grade > 0 compared
to 2 out of 17 with acute skin reactions RTOG grade 0–1 (mild),
odds ratio of 5.9 (95% CI 1.2–29.2) (Table 3). The wide CI is an effect
of few patients in the subgroups.
Patient-reported outcomes
Out of the 39 patients who underwent breast conserving sur-
gery, 20 patients noticed cosmetic differences between the treated
and untreated breast: 12 reported a minimal difference (score 2), 6Table 3
Comparison of acute and late RTOG assessments.
Late RTOG grade 0 Late RTOG grade > 0
Acute RTOG grade 0 1 0
Acute RTOG grade 1 14 2
Acute RTOG grade 2 17 11
Acute RTOG grade 3 7 8a fair difference (score 3) and 2 a substantial difference (score 4).
Eleven patients noticed differences in skin texture, and five
patients noticed differences in skin colour. There was no significant
difference between the two treatment arms. We did not ask the
patients who underwent a mastectomy if they experienced a cos-
metic difference between the treated and untreated breast, as such
a difference is obvious following mastectomy and may be a sensi-
tive and emotional topic to patients.
All seven patients with telangiectasia underwent a mastectomy
and ERT with bolus.Discussion
The present study identified no long-term sequelae following
six weeks of local corticosteroids used prophylactically to amelio-
rate radio dermatitis during adjuvant ERT in breast cancer patients.
The development of skin atrophy is of particular concern as cor-
ticosteroids used for months or years, locally or systemically, are
known to result in atrophy of the skin [22]. General fear of skin
atrophy may explain the unwillingness of physicians and patients
to use corticosteroid cream to prevent ERT dermatitis [23]. Studies
of normal skin of healthy volunteers exposed to a potent local cor-
ticosteroid for six weeks have shown that the skin becomes thinner
but the reduction of skin thickness, amounting to approximately
15%, returns to normal a few weeks after discontinuation of the
corticosteroids [22]. In our previous report, corticosteroids were
used for six weeks to prevent radio dermatitis.
In this study, clinical assessments via RTOG showed that one-
third of patients had minor late sequelae, such as slight fibrosis,
changes in pigmentation and telangiectasia, which mainly
occurred in the group treated with the moisturizer compared to
the group treated with corticosteroid with an odds ratio 3.2 (95%
CI: 1.0–10.1). Patients treated with moisturizer during ERT who
developed severe acute skin reactions experienced more late skin
sequelae compared to those treated with corticosteroid. Thus,
short course corticosteroid treatment during adjuvant ERT might
also have a protective effect against late sequelae. Future studies
should confirm this finding.
The cosmetic outcome of patients treated with breast-
conserving surgery and ERT appeared to be favourable, as half of
the patients did not report any differences between the treated
and untreated breast. On the other hand, in the group that
underwent mastectomy, seven patients out of 21 developed of
telangiectasia, which was visible and disturbing to them. Earlier
publications have shown that the development of telangiectasia
due to radiation is more common in patients with acute
radiodermatitis with moist desquamation (acute RTOG grade 3)
and radiation dose [6,8]. All patients with telangiectasia had an
acute RTOG score of 2–3 and had received a bolus.
A follow-up time of six years seems to be an adequate observa-
tion period [24]. In a study by Bentzen, [25] the length of time to
the expression of 90% of the final frequency of moderate to severe
complications was 3.2 years for fibrosis and 4.7 years for
telangiectasia.
12 E. Ulff et al. / Clinical and Translational Radiation Oncology 7 (2017) 9–12The sample we studied is of limited size, and thus, we cannot
exclude an effect of local corticosteroid on the direction of cuta-
neous sequelae. The use of quantitative measurements to depict
subtle effects did not detect any tendency towards atrophy. In con-
clusion, it remains unlikely that prophylactic corticosteroid treat-
ment to ameliorate acute radio dermatitis during adjuvant ERT of
breast cancer has any clinically relevant adverse effects on late skin
reactions.
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